ArticleHepatitis monthly2011
IL28B polymorphism, Explanation for Different Responses to Therapy in Hepatitis C Patients.
Article in Hepatitis monthly, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03296930 (Effect Of Interferon-Free Direct Acting Antiviral Agents For Treatment Of Hepatitis C Virus Patients On The Normal Kidney), which is not on this map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect Of Interferon-Free Direct Acting Antiviral Agents For Treatment Of Hepatitis C Virus Patients On The Normal Kidney
Who cites it
11 citing papers in PubMed.
- Treatment of chronic hepatitis C with pegylated interferon plus ribavirin in treatment-naïve 'real-life' patients in India.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2014Trial
- Real-life efficacy of generic sofosbuvir/ledipasvir for treatment of Iranian patients with chronic hepatitis C: A cohort study.Caspian journal of internal medicine · 2020Article
- Impact of IFNL4 rs12979860 and rs8099917 polymorphisms on response to Peg-Interferon-α and Ribavirin in patients with congenital bleeding disorder and chronic hepatitis C.Journal of clinical laboratory analysis · 2017Article
- Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline.Hepatitis monthly · 2016Review
- Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting Antivirals.Hepatitis monthly · 2016Review
- The ITPA and C20orf194 Polymorphisms and Hematological Changes During Treatment With Pegylated-Interferon Plus Ribavirin in Patients With Chronic Hepatitis C.Hepatitis monthly · 2016Article
- The Role of Polymorphisms Near the IL28B Gene on Response to Peg-Interferon and Ribavirin in Thalassemic Patients With Hepatitis C.Hepatitis monthly · 2016Article
- The interferon lambda 4 rs368234815 predicts treatment response to pegylated-interferon alpha and ribavirin in hemophilic patients with chronic hepatitis C.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2016Article
- Efficacy of 24-week pegylated interferon alpha and ribavirin combination therapy in highly selected patients infected with hepatitis C virus genotype 1.Hepatitis monthly · 2015Article
- Predicting the outcomes of combination therapy in patients with chronic hepatitis C using artificial neural network.Hepatitis monthly · 2014Article
- Sofosbuvir has come out of the magic box.Hepatitis monthly · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.